Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: Systematic review and meta-analysis of head-to-head studies

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Tiansheng ^a,d   Gou, Zhuoyue ^b   Wang, Fei ^c   Nling, Ma ^b   Zhai, Suo Di ^d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIPID; LIRAGLUTIDE; SITAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

BLOOD PRESSURE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; META ANALYSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FASTING; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; PYRAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZOLES;

EID: 84905472510     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103798     Document Type: Review

References (44)

1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1): 46-52. (Pubitemid 16162741)
2. De Fronzo RA (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58 (4): 773-95. doi:10.2337/db09-9028.
3. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-705. doi:10.1016/S0140-6736(06)69705-5. (Pubitemid 46048557)
4. Byetta® (2011) [package insert] San Diego, CA: Amylin Pharmaceuticals.
5. Bydureon® (2012) [package insert] San Diego, CA: Amylin Pharmaceuticals.
6. Victoza® (2010) [package insert] Princeton, NJ: Novo Nordisk.
7. European Medicines Agency lixisenatide: summary of product characteristics. Available: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/002445/WC500140401.pdf. Assessed 2014 April 15.
8. FDA news release: FDA approves Tanzeum to treat type 2 diabetes. Available: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm393289. htm. Assessed 2014 April 15.
9. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80(3): 952-957.
10. Januvia (2007) [package insert] Whitehouse Station, NJ: Merck and Co, Inc.
11. Onglyza (2011) [package insert] Princeton, NJ; Bristol-Myers Squibb Company.
12. Tradjenta (2011) [package insert] Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
13. European Medicines Agency Vildagliptin: summary of product characteristics. Available: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/000771/WC500020327.pdf. Assessed 2014 April 15.
14. Nesina (2013) [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.
15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, et al. (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6): 1364-1379. doi:10.2337/dc12-0413.
16. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents (2009) Available: www.nice.org.uk/nicemedia/live/12165/44318/44318. pdf.Assessed 2014 April 15.
17. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, et al. (2013) AACE comprehensive diabetes management algorithm. Endocr Pract 19 (2): 327-336.
18. Scheen AJ (2012) Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. Eur J Intern Med 23(2): 126-131. doi:10.1016/j.ejim.2011.10.007.
19. Madsbad S (2012) Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no. Eur J Intern Med 23(2): 132-136. doi:10.1016/j.ejim.2011.11.003.
20. Fakhoury WK, Lereun C, Wright D (2010) A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 86: 44-57. doi:10.1159/000314690.
21. Pinelli NR, Kathryn MH (2011) Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 45 (7-8): 850-860. doi:10.1345/aph.1Q024.
22. Brunton S (2014) GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract 68(5): 557-567. doi:10.1111/ijcp.12361.
23. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344: e1369. doi:10.1136/bmj.e1369.
24. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL (2012) Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344: d7771. doi:10.1136/bmj.d7771.
25. Monami M, Iacomelli I, Marchionni N, Mannucci E (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc 20: 224-35. doi:10.1016/j.numecd.2009.03. 015.
26. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2: CD006739. doi:10.1002/14651858.CD006739.pub2.
27. Esposito K, Cozzolino D, Bellastella G, Maiorino MI, Chiodini P, et al. (2011) Dipeptidyl peptidase-4 inhibitors and HbA1c target of, 7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 13: 594-603. doi:10.1111/j.1463-1326.2011.01380.x.
28. Arnolds S, Dellweg S, Clair J, Dain MP, Nauck MA, et al. (2010) Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and Metformin A proof-of-concept study. Diabetes Care 33(7): 1509-1515. doi:10.2337/dc09-2191.
29. Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH (2011) Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 13(11): 982-989. doi:10.1111/j.1463-1326.2011.01428.x.
30. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, et al. (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet 376(9739): 431-439. doi:10.1016/S0140-6736(10) 60590-9.
31. Best JH, Rubin RR, Peyrot M, Li Y, Yan P, et al. (2011) Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care 34(2): 314-319. doi:10.2337/dc10-1119.
32. Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, et al. (2013) Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia 56(7): 1503-1511. doi:10.1007/s00125- 013-2905-1.
33. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, et al. (2008). Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, crossover study. Curr Med Res Opin 24(10): 2943-2952. doi:10.1185/ 03007990802418851.
34. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, et al. (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. The Lancet 375(9724): 1447-1456. doi:10.1016/S0140-6736(10)60307-8.
35. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, et al. (2011) One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 65(4): 397-407. doi:10.1111/j.1742-1241.2011. 02656.x.
36. Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, González JG, et al. (2012) Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with Type 2 diabetes (DURATION-4) a 26-week double-blind study. Diabetes Care 35(2): 252-258. doi:10.2337/dc11-1107.
37. Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, et al. (2011) DURATION- 2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 28(6): 705-714. doi:10.2337/dc13-2760.
38. Higgins JP, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 Available: http://handbook.cochrane.org. Accessed 2014 April 15.
39. Amori RE, Lau J, Pittas AG (2007) Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206. doi:10.1001/jama.298.2.194. (Pubitemid 47057766)
40. Sterne J, Egger M, Moher D (2011) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available: http://hiv.cochrane.org/ sites/hiv. cochrane.org/files/uploads/Ch10-Reporting.pdf. Accessed 15 April 2014.
41. Deeks J, Higgins J, Altman D (2011) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available: http://hiv.cochrane.org/sites/hiv.cochrane.org/files/uploads/Ch09-Analysing.pdf. Accessed 15 April 2014.
42. Higgins J, Deeks J, Altman D (2011) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available: http://hiv.cochrane.org/ sites/hiv.cochrane.org/files/uploads/Ch16-Specialstatistics.pdf. Accessed 15 April 2014.
43. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629.
44. Cates CJ (2002) Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2: 1.doi:10.1186/1471-2288-2-1.